MedBen Rx Blog
Ask Better Questions for Safer Prescription Use
Nearly one-third of middle-aged Americans struggle with common health tasks, including remembering doctor instructions and properly following medication directions, according to new research. Simple details — when to take a medication, whether to take it with...
Drug Spending Growth Calls for Broader Pharmacy Strategies
U.S. pharmaceutical expenditures rose 12.7% in 2025 to $915.2 billion, according to a recent analysis in the American Journal of Health-System Pharmacy. Utilization drove most of the growth, led by high-cost therapies such as tirzepatide, semaglutide, and apixaban....
Traditional PBMs vs. MedBen Rx: A Side-by-Side Comparison
MedBen Rx is the fastest growing division of MedBen — and for good reason. Here’s how we stack up against traditional PBMs: CORE STRENGTHS OF MEDBEN RX OVER TRADITIONAL MODELS True Transparency & Pass-Through Traditional PBMs frequently use “spread...
Managing Specialty Drug Spend through Benefit Preservation
A recent Pharmaceutical Strategies Group analysis shows managing specialty drug costs is now the top priority for employer health plans —surpassing total cost of care. MedBen Rx’s Benefit Preservation Program addresses this by reducing specialty drug spend by an...
Biosimilars Show Strong Savings, but Broader Adoption Still Lags
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the...
The Clinical Difference: Evidence Over Rx Advertising
Heavy direct-to-consumer advertising of high-cost medications is fueling patient demand and placing added pressure on physicians to prescribe the drugs that patients recognize — even when lower-cost alternatives may be just as, or more, effective. The scale of this...
Biosimilars Takes Aim at Rising Specialty Drug Costs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Over 350 Brand-Name Drugs See a Price Increase in 2026
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
GLP-1 Spending Pressures States and Employers to Reassess Coverage
In recent months, a growing number of U.S. states have pulled back on covering GLP-1 medications for obesity under their Medicaid programs, even as the drugs remain broadly covered for diabetes. A recent KFF survey shows that while 16 state Medicaid programs still...
MedBen Rx Cuts Client’s First-Year Pharmacy Costs Nearly in Half
A new MedBen Rx client realized $1.19 million in combined plan and member savings in their first year – a 45.7% reduction, surpassing the $1.05 million projected savings. Per-member-per-month (PMPM) pharmacy costs tell the story: $233 under the previous PBM vs. just...
Prescription Patterns: How Employer Coverage Shapes Drug Utilization
A recent GoodRx list of the 20 most prescribed medications prompted MedBen Rx to take a closer look at how our own top prescriptions compare. Because GoodRx’s rankings largely reflect individuals who pay for medications out of pocket – rather than through...
Employers Take a Variety of Approaches to GLP-1 Coverage
A recent International Foundation of Employee Benefit Plans survey shows that while employers are open to covering GLP-1 drugs for diabetes, they’re far more hesitant to do so for weight loss. Over half of corporate and multiemployer/public plans cover GLP-1s for...